Key points from article :
Beacon Therapeutics, a British-US biotech company, secured $170 million in funding to develop gene therapies for retinal diseases, including age-related macular degeneration (AMD).
The company's innovative approach involves using gene therapy to treat dry AMD, a leading cause of vision loss in older adults.
Their therapy is delivered via an intravitreal injection, a less invasive method compared to traditional surgery, potentially making it more accessible.
This funding round brings Beacon's total raised capital to roughly $290 million, allowing them to advance their therapies into clinical trials.
The investment was led by Forbion, with participation from other notable investors, and also led to the expansion of Beacon's board of directors.
The company aims to save and restore vision for patients with various retinal diseases through their ongoing research and development efforts.
